Progestins
PreclinicalSmall molecule
Progestins is one of 101 small molecule programs targeting Endometrial Cancer. It is currently in Preclinical.
2
Indications
4
Total Trials
1
Active Trials
100
Competitors
Pipeline
Status by Indication[3][1]
Competition
Competitive Landscape
103 competitors in Endometrial Cancer
#DrugCompanyPhaseTrials
1Taxol
TevaPhase 3
Keytruda
Merck & Co.Phase 3
Femara
NovartisPhase 3
Paraplatin
AAvyxa
Phase 3
Platinol
MMcNeil Consumer & Specialty Pharmaceuticals, a Division of McNeil-PPC, Inc.
Phase 3
Megace
Bristol-Myers SquibbPhase 3
Lenvima
EisaiPhase 3
Lynparza
AstraZenecaPhase 3
Depo-Provera
Eli LillyPhase 3
Tecentriq
RochePhase 3
Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.
Timeline
Expected Milestones
Clinical
Trials by Indication[1]
Endometrial Cancer1 trial
Sources
References
- [1]
- [2]
- [3]Open Targets Platform — Drug–disease associations for Progestins. EMBL-EBI & Wellcome Sanger Institute.
- [4]
Details